Let’s Partner to Win
Guided by Play-to-Win strategy, Sanofi Partnering works with innovators to bring the most promising medicines to patients. We are inspired by the possibilities of transformative science and the creativity of innovators to change the lives of patients worldwide.
External collaborations play a major role in Sanofi's pipeline development. Over the years, we have transformed patients’ lives by delivering breakthrough medicines, working in close partnership with innovators. We win with our partners.
Together we can be faster, more ambitious in clinical development, bring products to more patients in more geographies, optimize CMC and manufacturing, and create a powerful ecosystem supporting our medicines.
"We’re constantly on the lookout for game-changing medicine. Our focus is transformation – building tomorrow’s healthcare, with partners striving to bring innovation to patients worldwide."
Alban de La Sablière, Head of Sanofi Partnering
Sanofi Partnering invests in early-stage companies through Sanofi Ventures, develops win-win partnerships through BD&L while building a strong and seamless collaboration to ensure the successful development and commercialization of medicines through Alliance Management.
Because we are keenly aware that time is a scarce resource, we value a straightforward and direct communication and a collaborative approach to problem solving. All of that with direct access and involvement of Sanofi senior leadership. Our goal is to make it simple while delivering the breadth of our expertise. We believe this is key to bringing transformative medicines to patients with our partners.
Highlights
Partnering for the Future
John Reed, Global Head of R&D, and Alban de La Sablière, Head of Sanofi Partnering, share how Sanofi's latest partnerships can accelerate the pace of R&D innovation and fuel its long-term success in oncology and immunology.
Partnering in a Few Figures
Testimonies of our Partners
Dr Antoine Tarral, Head of the sleeping sickness clinical programme at DNDi
“Following the development of fexinidazole, the first all-oral treatment for sleeping sickness which received a positive scientific opinion from the European Medicines Agency (EMA) in 2018, we are thrilled to continue our long-standing relationship with Sanofi on sleeping sickness, a disease which is almost always fatal without treatment. Fexinidazole has greatly improved treatment options for patients, but acoziborole would provide, once approved, an even more attractive treatment option, because it can be administered as a single oral dose and could give a radical boost to the final stage of sleeping sickness elimination.”
Emma Walmsley, Chief Executive Officer, GSK
“This collaboration brings together two of the world’s largest vaccines companies. By combining our scientific expertise, technologies and capabilities, we believe that we can help accelerate the global effort to develop a vaccine to protect as many people as possible from Covid-19.”
Christian Thirion, Ph.D., CEO and Co‑founder of SIRION
“We are delighted to be collaborating with Sanofi. Sanofi is an ideal partner with decades-long experience in treating a multitude of disorders and exploring viral vectors as a therapeutic modality.
AAV vectors with improved efficacy can enable quickly entering into clinical trials with efficient, safe low doses and scalable therapeutic candidates and can expand the impact of gene therapies.” Sabine Ott, Senior Vice President BD & Licensing at SIRION added: “We believe that through this exclusive partnership with Sanofi within these large disease fields, AAV-based gene therapies will provide novel treatment options to many millions of patients worldwide suffering from these diseases”.
